Medical News

RSS

Covidien receives Brazilian approval for Solitaire FR Revascularization Device

Covidien, a leading global provider of healthcare products, today announced that the Solitaire FR Revascularization Device has been approved by Brazil's National Health Surveillance Agency. The Solitaire FR device is used to restore blood flow to the brain in patients suffering acute ischemic stroke.

20 Jul 2012

Actinium completes Actimab-A Phase I/II study on Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.

20 Jul 2012

Longer looks: Physicians and assisted suicide; Avoid getting sick in July

Peggy Sutherland was ready to die. The morphine oozing from a pump in her spine was no match for the pain of lung cancer, which had evaded treatment and invaded her ribs. … Sutherland, 68, decided to use Oregon's "Death With Dignity Act," which allows terminally-ill residents to end their lives after a 15-day requisite waiting period by self-administering a lethal prescription drug. ... But not all doctors are on board with the law.

20 Jul 2012

BrainStorm completes registered public offering of common stock

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, today announced that it completed a registered public offering of 19,818,972 shares of common stock at a price per share of $0.29 and warrants to purchase 14,864,229 shares of common stock at an exercise price of $0.29 per share, representing gross proceeds of $5,747,502.

20 Jul 2012

TLC announces first Laser Cataract Surgeries to be performed in Canada

TLC Laser Eye Centers is excited to announce the first Laser Cataract Surgeries to be performed in Canada, using an approved femtosecond laser, will take place at TLC's Mississauga center on July 24, 2012.

20 Jul 2012

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

The first patient has now been enrolled into the Phase 1 clinical trial sponsored by Viral Genetics' and supported by a donation from Scott and White Foundation. The trial will study Metabolic Disruption Technology (MDT) compounds in combination with an existing cancer therapy to treat drug-resistant ovarian cancer.

20 Jul 2012

Blockade Medical’s Barricade Coil System receives CE Mark

Blockade Medical announced today that it has received CE Mark (Conformité Européenne) for its Barricade Coil System. The Barricade Coil System is designed to remove or endovascularly occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels.

20 Jul 2012

WorldOne announces acquisition of Sermo

WorldOne, the global leader in healthcare insights and intelligence, today announced that it has acquired Sermo, the largest online community of U.S. physicians.

20 Jul 2012

Lifescript introduces new online health center for women with fibromyalgia

Lifescript.com, a women's health and wellness website headquartered in Mission Viejo, Calif., has launched a new online Fibromyalgia Health Center, designed to help women treat and reduce the frustrations and pain of fibromyalgia.

20 Jul 2012

Roundup: Minn. health care spending slows; Fla. counties may reconsider Medicaid lawsuit against state; Accessing dental care in Georgia

The state Health Department reports the rate of health care spending in Minnesota has slowed to its lowest point since 1997. Health care costs are still rising, but at a much slower pace -- 2.2 percent between 2009 and 2010. State Health Economist Stefan Gildemeister said the recession was a major factor in why Minnesotans spent less on health care. He said many lost their insurance when they lost their jobs and others who kept their jobs were more cautious.

20 Jul 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012